Interleukin-1-receptor antagonist in type 2 diabetes mellitus
Open accessThe DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The expression of interleukin-1-receptor antagonist is reduced in pancreatic islets of patients with type 2 diabetes mellitus, and high glucose concentrations induce the production of interleukin-1beta in human pancreatic beta cells, leading to impaired insulin secretion, decreased cell proliferation, and apoptosis. METHODS: In this double-blind, parallel-group trial involving 70 patients with type 2 diabetes, we randomly assigned 34 patients to receive 100 mg of anakinra (a recombinant human interleukin-1-receptor antagonist) subcutaneously once daily for 13 weeks and 36 patients to receive placebo. At baseline and at 13 weeks, all patients underwent an oral glucose-tolerance test, followed by an intravenous bolus of 0.3 g of glucose per kilogram of body weight, 0.5 mg of glucagon, and 5 g of arginine. In addition, 35 patients underwent a hyperinsulinemic-euglycemic clamp study. The primary end point was a change in the level of glycated hemoglobin, and secondary end points were changes in beta-cell function, insulin sensitivity, and inflammatory markers. RESULTS: At 13 weeks, in the anakinra group, the glycated hemoglobin level was 0.46 percentage point lower than in the placebo group (P=0.03); C-peptide secretion was enhanced (P=0.05), and there were reductions in the ratio of proinsulin to insulin (P=0.005) and in levels of interleukin-6 (P<0.001) and C-reactive protein (P=0.002). Insulin resistance, insulin-regulated gene expression in skeletal muscle, serum adipokine levels, and the body-mass index were similar in the two study groups. Symptomatic hypoglycemia was not observed, and there were no apparent drug-related serious adverse events. CONCLUSIONS: The blockade of interleukin-1 with anakinra improved glycemia and beta-cell secretory function and reduced markers of systemic inflammation. (ClinicalTrials.gov number, NCT00303394 [ClinicalTrials.gov].).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Recently, early interventions with insulin therapy in newly diagnosed T2D ( 83 ), with targeted anti-inflammatory therapy using an IL-1β antagonist ( 84 ), and with GLP-1 receptor agonists ( 85 ) have demonstrated that β-cell dysfunction can be reversed temporarily.”
From β-Cell Failure in Type 2 Diabetes: Postulated Mechanisms and Prospects for Prevention and Treatment (2014) · cites this paper as [84]
In the citing paper
“improved glucose control required fewer glucose-lowering agents, including insulin”
From Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future (2014) · cites this paper as [135]
In the citing paper
“a greater proportion of participants achieved a HbA1c <7%135”
From Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future (2014) · cites this paper as [135]
In the citing paper
“A benefit for anakinra was also shown in a small, randomized trial of 70 patients with type 2 diabetes109.”
From Sterile inflammation: sensing and reacting to damage (2010) · cites this paper as [109]
In the citing paper
“However, the clinical study was still small and was not designed to determine optimal dosing, duration of use or long-term outcomes in disease control.”
From Sterile inflammation: sensing and reacting to damage (2010) · cites this paper as [109]
3 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Mootha, V. K., Lindgren, C. M., Eriksson, K.-F., Subramanian, A., Sihag, S., Lehar, J., Puigserver, P., Carlsson, E., Ridderstråle, M., Laurila, E., et al. (2003) · Nature Genetics · doi:10.1038/ng1180 · Cited by 10,197
Use and Abuse of HOMA Modeling
Wallace, T. M., Levy, J. C., & Matthews, D. R. (2004) · Diabetes Care · doi:10.2337/diacare.27.6.1487 · Cited by 5,114
Biologic basis for interleukin-1 in disease.
Dinarello, C. (1996) · Blood · doi:10.1182/blood.v87.6.2095.bloodjournal8762095 · Cited by 4,344
β-Cell Deficit and Increased β-Cell Apoptosis in Humans With Type 2 Diabetes
Butler, A. E., Janson, J., Bonner-Weir, S., Ritzel, R., Rizza, R. A., & Butler, P. C. (2003) · Diabetes · doi:10.2337/diabetes.52.1.102 · Cited by 4,011
The Triumvirate: β-Cell, Muscle, Liver: A Collusion Responsible for NIDDM
DeFronzo, R. A. (1988) · Diabetes · doi:10.2337/diab.37.6.667 · Cited by 2,456
U.K. Prospective Diabetes Study Group (1995) · Diabetes · doi:10.2337/diab.44.11.1249 · Cited by 1,923
Glucose-induced β cell production of IL-1β contributes to glucotoxicity in human pancreatic islets
Maedler, K., Sergeev, P., Ris, F., Oberholzer, J., Joller-Jemelka, H. I., Spinas, G. A., Kaiser, N., Halban, P. A., & Donath, M. Y. (2017) · Journal of Clinical Investigation · doi:10.1172/jci92172 · Cited by 1,114
Self-citationGlucose-induced β cell production of IL-1β contributes to glucotoxicity in human pancreatic islets
Maedler, K., Sergeev, P., Ris, F., Oberholzer, J., Joller-Jemelka, H. I., Spinas, G. A., Kaiser, N., Halban, P. A., & Donath, M. Y. (2002) · Journal of Clinical Investigation · doi:10.1172/jci200215318 · Cited by 1,005
Self-citationNeonatal-Onset Multisystem Inflammatory Disease Responsive to Interleukin-1β Inhibition
Goldbach-Mansky, R., Dailey, N. J., Canna, S. W., Gelabert, A., Jones, J., Rubin, B. I., Kim, H. J., Brewer, C., Zalewski, C., Wiggs, E., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa055137 · Cited by 930
Diagnosis and Classification of Diabetes Mellitus
American Diabetes Association (2006) · Diabetes Care · doi:10.2337/diacare.29.s1.06.s43 · Cited by 924
Cited by
Items 801–900 of 1,001
van Greevenbroek, M. M. J., Schalkwijk, C. G., & Stehouwer, C. D. A. (2016) · F1000Research · doi:10.12688/f1000research.8971.1 · Cited by 45
Urwyler, S. A., Ebrahimi, F., Burkard, T., Schüetz, P., Poglitsch, M., Müeller, B., Donath, M. Y., & Christ‐Crain, M. (2020) · Hypertension · doi:10.1161/hypertensionaha.119.13982 · Cited by 40
“Accordingly, IL-1 antagonism has been shown to improve glycemia.(34) Interestingly, we found that patients with an impaired fasting glucose compared to patients with normal morning glucose levels had a higher between-group increase in Ang (1–7) compared to patients with normal glucose levels.”
BackgroundResultSelf-citationInterleukin-38 in Health and Disease
de Graaf, D. M., Teufel, L. U., Joosten, L. A. B., & Dinarello, C. A. (2022) · Cytokine · doi:10.1016/j.cyto.2022.155824 · Cited by 43
Immunomodulation at epithelial sites by obesity and metabolic disease
Cheung, K. P., Taylor, K. R., & Jameson, J. (2011) · Immunologic Research · doi:10.1007/s12026-011-8261-7 · Cited by 42
Anti‐inflammatory effects of resolvins in diabetic nephropathy: Mechanistic pathways
Yaribeygi, H., Atkin, S. L., Simental‐Mendía, L. E., Barreto, G. E., & Sahebkar, A. (2019) · Journal of Cellular Physiology · doi:10.1002/jcp.28315 · Cited by 40
“Some clinical trials have shown that anti‐inflammatory therapy improves glycemic control and β‐cell function in DM (Goldfine et al., 2010; Larsen et al., 2007).”
BackgroundKlüppelholz, B., Thorand, B., Köenig, W., Gala, T. D. L. H., Meisinger, C., Huth, C., Giani, G., Franks, P. W., Roden, M., Rathmann, W., et al. (2015) · Diabetologia · doi:10.1007/s00125-015-3679-4 · Cited by 43
What causes type 1 diabetes? Lessons from animal models
Buschard, K. (2011) · Apmis · doi:10.1111/j.1600-0463.2011.02765.x · Cited by 44
Obesity, COVID-19 and innate immunometabolism
Gleeson, L. E., Roche, H. M., & Sheedy, F. J. (2020) · British Journal Of Nutrition · doi:10.1017/s0007114520003529 · Cited by 41
Lipid deposition and metaflammation in diabetic kidney disease
Mitrofanova, A. V., Fontanella, A. M., Merscher, S., & Fornoni, A. (2020) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2020.09.004 · Cited by 42
Verma, A. K., Bhatt, D., Goyal, Y., Dev, K., Beg, M. M. A., Alsahli, M. A., & Rahmani, A. H. (2021) · Journal of Multidisciplinary Healthcare · doi:10.2147/jmdh.s285469 · Cited by 43
The modern interleukin-1 superfamily: Divergent roles in obesity.
Lee, M. K. S., Yvan-Charvet, L., Masters, S., & Murphy, A. (2016) · Seminars in Immunology · doi:10.1016/j.smim.2016.10.001 · Cited by 33
Emerging role of macrophages in non-infectious diseases: An update
Yousaf, H., Khan, M. I. U., Ali, I., Munir, M. U., & Lee, K. Y. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.114426 · Cited by 39
Buzzetti, R., Spoletini, M., Zampetti, S., Campagna, G., Marandola, L., Panimolle, F., Dotta, F., Tiberti, C., & for the NIRAD Study Group (NIRAD 8) (2015) · Diabetes Care · doi:10.2337/dc14-1638 · Cited by 41
Interleukin-1 in Lipopolysaccharide Induced Chorioamnionitis in the Fetal Sheep
Berry, C. A., Nitsos, I., Hillman, N. H., Pillow, J. J., Polglase, G. R., Kramer, B. W. W., Kemp, M. W., Newnham, J. P., Jobe, A. H., & Kallapur, S. G. (2011) · Reproductive Sciences · doi:10.1177/1933719111404609 · Cited by 39
Novel Mediators of Adipose Tissue and Muscle Crosstalk
Indrakusuma, I., Sell, H., & Eckel, J. (2015) · Current Obesity Reports · doi:10.1007/s13679-015-0174-7 · Cited by 38
New Developments in Diabetes Management: Medications of the 21st Century
Fonseca, V. A. (2014) · Clinical Therapeutics · doi:10.1016/j.clinthera.2014.01.018 · Cited by 38
The cytokine milieu of diabetic wounds
DeClue, C. E., & Shornick, L. P. (2015) · Diabetes Management · doi:10.2217/dmt.15.44 · Cited by 42
Increased Levels of AIM2 and Circulating Mitochondrial DNA in Type 2 Diabetes.
Cataño, Y., Uresti‐Rivera, E. E., García-Jacobo, R. E., Portales‐Pérez, D. P., Yadira, B., Rivera, J. G. R., Amaro, R. G., Enciso‐Moreno, J. A., & García-Hernández, M. H. (2018) · PubMed · doi:10.22034/iji.2018.39378 · Cited by 47
Innate immune stimulation of whole blood reveals IFN-1 hyper-responsiveness in type 1 diabetes
Rodrigues, K. B., Dufort, M. J., Llibre, A., Speake, C., Rahman, M. J., Bondet, V., Quiel, J. A., Linsley, P. S., Greenbaum, C. J., Duffy, D., et al. (2020) · Diabetologia · doi:10.1007/s00125-020-05179-4 · Cited by 40
NLRP3 Inflammasome Biomarker—Could Be the New Tool for Improved Cardiometabolic Syndrome Outcome
Suceveanu, A., Mazilu, L., Katsiki, N., Parepa, I. R., Voinea, F., Stoian, A. P., Rizzo, M., Botea, F., Herlea, V., Şerban, D., et al. (2020) · Metabolites · doi:10.3390/metabo10110448 · Cited by 41
“Anakinra, an IL-1 receptor antagonist used for rheumatoid arthritis treatment [47] and glyburide, a sulfonylurea medication inhibiting NLRP3 inflammasome activation by preventing the secretion of IL-1β [48], are just two drugs sustaining the use of NLRP3 inflammasome-targeted therapies for T2D and CMS.”
FOXO1 involvement in insulin resistance-related pro-inflammatory cytokine production in hepatocytes
Miao, H., Zhang, Y., Lu, Z., Liu, Q., & Gan, L. (2012) · Inflammation Research · doi:10.1007/s00011-011-0417-3 · Cited by 38
Akash, M. S. H., Rehman, K., Sun, H., & Chen, S. (2013) · Pharmaceutical Development and Technology · doi:10.3109/10837450.2013.775158 · Cited by 38
Cardoso, C. R. L., Leite, N. C., Carlos, F., Loureiro, A. A., Viegas, B. B., & Salles, G. F. (2017) · Diabetes Care · doi:10.2337/dc17-0374 · Cited by 40
Ruscitti, P., Cipriani, P., Cantarini, L., Liakouli, V., Vitale, A., Carubbi, F., Berardicurti, O., Galeazzi, M., Valenti, M., & Giacomelli, R. (2015) · Journal of Medical Case Reports · doi:10.1186/s13256-015-0603-y · Cited by 37
Common biological mechanisms between bipolar disorder and type 2 diabetes: Focus on inflammation
Sharma, A. N., Bauer, I. E., Sanches, M., Galvez, J. F., Zunta‐Soares, G. B., Quevedo, J., Kapczinski, F. P., & Soares, J. C. (2014) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2014.06.005 · Cited by 38
“, 2010) and its role on the activation of other cytokines on IL-1R activation (Dinarello, 2000; Larsen et al., 2007).”
BackgroundResultParazzoli, S. D., Harmon, J. S., Vallerie, S. N., Zhang, T., Zhou, H., & Robertson, R. P. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.364612 · Cited by 37
Morikawa, S., Kaneko, N., Okumura, C., Taguchi, H., Kurata, M., Yamamoto, T., Osawa, H., Nakanishi, A., Zako, T., & Masumoto, J. (2018) · International Journal of Immunopathology and Pharmacology · doi:10.1177/2058738418788749 · Cited by 38
Frühbeck, G., Catalán, V., Ramírez, B., Valentí, V., Becerril, S., Rodríguez, A., Moncada, R., Baixauli, J., Silva, C., Escalada, J., et al. (2022) · Journal of Inflammation Research · doi:10.2147/jir.s354095 · Cited by 39
The Role of Interleukins in the Pathogenesis of Dermatological Immune-Mediated Diseases
Turchin, I., & Bourcier, M. (2022) · Advances in Therapy · doi:10.1007/s12325-022-02241-y · Cited by 39
Treatment of Periodontal Inflammation in Diabetic Rats with IL-1ra Thermosensitive Hydrogel
Liu, Y., Liu, C., Wang, C., Zhang, Q., Qu, X., Chen, L., Si, C., & Wang, L. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232213939 · Cited by 38
Interleukin-Targeted Therapy for Metabolic Syndrome and Type 2 Diabetes
Maedler, K., Dharmadhikari, G., Schumann, D., & Størling, J. (2011) · Handbook of experimental pharmacology · doi:10.1007/978-3-642-17214-4_11 · Cited by 43
Jain, S. K., Huning, L., & Micinski, D. (2014) · Metabolic Syndrome and Related Disorders · doi:10.1089/met.2014.0022 · Cited by 37
Kralisch, S., Sommer, G., Weise, S., Lipfert, J., Lössner, U., Kamprad, M., Schröck, K., Blüher, M., Stümvoll, M., & Faßhauer, M. (2009) · FEBS Letters · doi:10.1016/j.febslet.2009.03.015 · Cited by 37
Autoinflammation: translating mechanism to therapy
Doherty, T. A., Brydges, S. D., & Hoffman, H. M. (2011) · Journal of Leukocyte Biology · doi:10.1189/jlb.1110616 · Cited by 39
Feng, Y., Zhao, D., Zhang, N., Yu, C., Qiang, Z., Thijs, L., & Staessen, J. A. (2016) · PLoS ONE · doi:10.1371/journal.pone.0153171 · Cited by 37
Microarray-based identification of novel biomarkers in IL-1-mediated diseases
Allantaz, F., Chaussabel, D., Banchereau, J., & Pascual, V. (2007) · Current Opinion in Immunology · doi:10.1016/j.coi.2007.10.003 · Cited by 37
High-Risk Cardiovascular Patients: Clinical Features, Comorbidities, and Interconnecting Mechanisms
Schuett, K. A., Lehrke, M., Marx, N., & Burgmaier, M. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00591 · Cited by 43
Li, H., Zhu, H., Ge, T., Wang, Z., & Zhang, C. (2021) · Stem Cell Reviews and Reports · doi:10.1007/s12015-021-10139-5 · Cited by 37
Reddy, M. A., Samara, V. A., Das, S., Tanwar, V. S., Ganguly, R., Wang, M., Lanting, L. L., Zhang, L., Abdollahi, M., Chen, Z., et al. (2021) · JCI Insight · doi:10.1172/jci.insight.143289 · Cited by 42
Metabolic Abnormalities and Cardiovascular Risk Factors in Children with Myositis
Coyle, K., Rother, K. I., Weise, M., Ahmed, A. E. E., Miller, F. W., & Rider, L. G. (2009) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2009.06.009 · Cited by 38
Burke, S. J., Lu, D., Sparer, T. E., Karlstad, M. D., & Collier, J. J. (2014) · Molecular Immunology · doi:10.1016/j.molimm.2014.05.019 · Cited by 36
Serum interleukin-1β in subjects with abdominal obesity and periodontitis
Satpathy, A., Ravindra, S., Thakur, S. L., Kulkarni, S. S., Porwal, A., & Panda, S. (2015) · Obesity Research & Clinical Practice · doi:10.1016/j.orcp.2015.01.005 · Cited by 36
Diabetes treatment in 2025: can scientific advances keep pace with prevalence?
Shomali, M. E. (2012) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/2042018812465639 · Cited by 40
Pancreatic islet dysfunction in type 2 diabetes mellitus
Hu, F., Qiu, X., & Bu, S. (2018) · Archives of Physiology and Biochemistry · doi:10.1080/13813455.2018.1510967 · Cited by 38
“…Shizhong Bu bushizhong@nbu.edu.cn Diabetes Research Center, Ningbo University, 818 Fenghua Road, Ningbo 315211, Zhejiang, PR China 2018 Informa UK Limited, trading as Taylor & Francis Group blinded, randomized trial in patients with poorly controlled type 2 diabetes (Larsen et al. 2007).”
BackgroundCeramides: A new player in the inflammation–insulin resistance paradigm?
Gill, J. M. R., & Sattar, N. A. (2009) · Diabetologia · doi:10.1007/s00125-009-1546-x · Cited by 36
Relevance and consequence of chronic inflammation for obesity development
Rück, L., Wiegand, S., & Kühnen, P. (2023) · Molecular and Cellular Pediatrics · doi:10.1186/s40348-023-00170-6 · Cited by 35
Arous, C., Ferreira, P. G., Dermitzakis, E. T., & Halban, P. A. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.611111 · Cited by 35
2011 Update: antigen-specific therapy in type 1 diabetes
Michels, A. W., & von Herrath, M. (2011) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0b013e32834803ae · Cited by 38
Yu, D., Xu, Z., Yin, X., Zheng, F., Lin, X., Pan, Q., & Li, H. (2015) · PLoS ONE · doi:10.1371/journal.pone.0142848 · Cited by 37
IL-1beta promotes the age-associated decline of beta cell function
Böni‐Schnetzler, M., Méreau, H., Rachid, L., Wiedemann, S. J., Schulze, F., TRIMIGLIOZZI, K. A., Meier, D. T., & Donath, M. Y. (2021) · iScience · doi:10.1016/j.isci.2021.103250 · Cited by 36
Self-citationREDD1 promotes obesity-induced metabolic dysfunction via atypical NF-κB activation
Lee, D., Kim, T., Byeon, J., Park, M., Kim, S., Kim, J., Choi, S., Lee, G., Park, C., Lee, K. W., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-34110-1 · Cited by 35
Christensen, C. S., Christensen, D. P., Lundh, M., Dahllöf, M. S., Haase, T. N., Velasquez, J. M., Laye, M. J., Mandrup-Poulsen, T., & Solomon, T. P. J. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-4506 · Cited by 34
Self-citationIAPP boosts islet macrophage IL-1 in type 2 diabetes
Mandrup-Poulsen, T. R. (2010) · Nature Immunology · doi:10.1038/ni1010-881 · Cited by 36
Self-citationCauci, S., Santolo, M. D., Ryckman, K. K., Williams, S. M., & Banfi, G. (2010) · BMC Medical Genetics · doi:10.1186/1471-2350-11-29 · Cited by 35
Chang, J., Chang, C., Chien, Y., Lin, S. S.-H., Cheng-Shiuan, T., Bai, C., & Chao, K. (2013) · BMC Pediatrics · doi:10.1186/1471-2431-13-123 · Cited by 40
Davis, B. K., & Ting, J. P.-Y. (2010) · Nature Immunology · doi:10.1038/ni0210-105 · Cited by 35
Role of Innate Immunity in Diabetes and Metabolism: Recent Progress in the Study of Inflammasomes
Lee, M. (2011) · Immune Network · doi:10.4110/in.2011.11.2.95 · Cited by 35
Boriushkin, E., Wang, J. J., Li, J., Bhatta, M., & Zhang, S. X. (2016) · Scientific Reports · doi:10.1038/srep25013 · Cited by 35
The adipokine SAA3 is induced by interleukin‐1β in mouse adipocytes
Sommer, G., Weise, S., Kralisch, S., Scherer, P. E., Lössner, U., Blüher, M., Stümvoll, M., & Faßhauer, M. (2008) · Journal of Cellular Biochemistry · doi:10.1002/jcb.21782 · Cited by 35
Role of Interleukins in Type 1 and Type 2 Diabetes
Asif, R., Khalid, A., Mercantepe, T., Klisic, A. N., Rafaqat, S., Rafaqat, S., & Mercantepe, F. (2025) · Diagnostics · doi:10.3390/diagnostics15151906 · Cited by 41
“IL-1 β , a potent pro-inflammatory cytokine, has been targeted in clinical trials with IL-1 receptor antagonists like anakinra, demonstrating improved glycemic control and β -cell preservation in T2D patients [53,54].”
Lin, Y., Peng, Y., He, S., Xu, J., Shi, Y., Su, Y., Zhu, C., Zhang, X., Zhou, R., & Cui, D. (2018) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2018.01.020 · Cited by 34
“Several studies had shown that patients with DM achieved improvement in IR after anakinra, an analog of IL-1ra, treatment ([46]).”
BackgroundTsuchiya, M., Sekiai, S., Hatakeyama, H., Koide, M., Chaweewannakorn, C., Yaoita, F., Tan–No, K., Sasaki, K., Watanabe, M., Sugawara, S., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.04.067 · Cited by 35
The Future of IL-1 Targeting in Kidney Disease
Afşar, B., Covic, A. C., Ortíz, A., Afşar, R. E., & Kanbay, M. (2018) · Drugs · doi:10.1007/s40265-018-0942-2 · Cited by 35
Conte, E., Andreini, D., Magnoni, M., Masson, S., Mushtaq, S., Berti, S. L., Canestrari, M., Casolo, G., Gabrielli, D., Latini, R., et al. (2020) · Journal of cardiovascular computed tomography · doi:10.1016/j.jcct.2020.03.005 · Cited by 35
Johansen, M. Y., Karstoft, K., MacDonald, C., Hansen, K. B., Ellingsgaard, H., Hartmann, B., Albrechtsen, N. J. W., Vaag, A. A., Holst, J. J., Pedersen, B. K., et al. (2020) · Diabetologia · doi:10.1007/s00125-020-05249-7 · Cited by 35
Self-citationAnti-cytokine vaccination in autoimmune diseases
Delavallée, L., Duvallet, E., Semerano, L., Assier, É., & Boissier, M. (2010) · Swiss Medical Weekly · doi:10.4414/smw.2010.13108 · Cited by 34
Andersen, G. Ø., Ueland, T., Knudsen, E. C., Scholz, H., Yndestad, A., Sahraoui, A., Smith, C., Lekva, T., Otterdal, K., Halvorsen, B. L., et al. (2011) · Diabetes · doi:10.2337/db10-1493 · Cited by 36
Chan, M. W. Y., & Viswanathan, S. (2019) · Cytotherapy · doi:10.1016/j.jcyt.2019.02.002 · Cited by 37
High Resolution Clinical Model-Based Assessment of Insulin Sensitivity
Lotz, T. (2007) · UC Research Repository (University of Canterbury) · doi:10.26021/2196 · Cited by 39
Nyblom, H. K., Bugliani, M., Fung, E., Boggi, U., Zubarev, R., Marchetti, P., & Bergsten, P. (2009) · Journal of Proteome Research · doi:10.1021/pr9006816 · Cited by 33
Link, K., Allio, I., Rand, J. S., & Eppler, E. (2013) · General and Comparative Endocrinology · doi:10.1016/j.ygcen.2013.04.029 · Cited by 36
Krakauer, T. (2015) · Medical Hypotheses · doi:10.1016/j.mehy.2015.08.019 · Cited by 36
“The pathogenic role of inflammasome activation in T2D is evidenced by the beneficial effects of ankinara, an IL1b receptor antagonist, in improved glycemia and b cell function in T2D [18].”
BackgroundMaiorino, M. I., Bellastella, G., Giugliano, D., & Esposito, K. (2016) · Endocrine · doi:10.1007/s12020-016-0993-7 · Cited by 34
“The first study [27] that tested the metabolic effect of IL-1b inhibition with Anakinra in type 2 diabetes reported benefits on both hyperglycemia and secretory function of insulin associated with reduced C-reactive protein (CRP) levels (Table 1).”
BackgroundCiortan, L., Macarie, R. D., Cecoltan, S., Vadana, M., Tucureanu, M. M., Mihaila, A. C., Droc, I., Butoi, E. D., & Mânduțeanu, I. (2020) · Polymers · doi:10.3390/polym12122786 · Cited by 34
“Therefore, IL-1β was found to be increased in stenotic aortic valves [26], with increased secretion induced by hyperglycemia, becoming a therapeutic target in patients with T2DM [27].”
BackgroundAbu-Shahba, N., Mahmoud, M., El-Erian, A. M., Husseiny, M. I., Eldeen, G. N., Helwa, I., Amr, K. S., ElHefnawi, M., Othman, A. I., Ibrahim, S., et al. (2021) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2021.106072 · Cited by 33
Abedi, F., Ghandforoushan, P., Adeli, F., Yousefnezhad, M., Mohammadi, A., Moghaddam, S. V., & Davaran, S. (2023) · Materials Today Chemistry · doi:10.1016/j.mtchem.2022.101372 · Cited by 38
Transcriptional Regulation of Chemokine Genes: A Link to Pancreatic Islet Inflammation?
Burke, S. J., & Collier, J. J. (2015) · Biomolecules · doi:10.3390/biom5021020 · Cited by 36
Impaired beta cell function is present in nondiabetic rheumatoid arthritis patients
Ferraz‐Amaro, I., García-Dopico, J. A., Medina-Vega, L., González-Gay, M. Á., & Díaz‐González, F. (2013) · Arthritis Research & Therapy · doi:10.1186/ar4149 · Cited by 33
Alpha cells, the main source of IL-1β in human pancreas
Anquetil, F., Sabouri, S., Thivolet, C. H., Calvo, T. R., Zapardiel‐Gonzalo, J., Amirian, N., Schneider, D., Castillo, E., Lajevardi, Y., & von Herrath, M. G. (2017) · Journal of Autoimmunity · doi:10.1016/j.jaut.2017.03.006 · Cited by 37
Lambertucci, F., Arboatti, A., Sedlmeier, M. G., Motiño, O., Álvarez, M. D. L., Ceballos, M. P., Villar, S. R., Roggero, E., Monti, J. A., Pisani, G. B., et al. (2018) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2018.04.013 · Cited by 35
“The potential of the liver as a metabolic target for IL-1β in obesity could be inferred from the finding that the IL-1 receptor a (IL-1Ra) antagonist not only improved stimulated insulin levels, but also decreased fasting glucose, largely reflecting attenuated hepatic glucose production [33].”
BackgroundEvidence of an anti-inflammatory toll-like receptor 9 (TLR 9) pathway in adipocytes
Thomalla, M., Schmid, A., Neumann, E., Pfefferle, P. I., Müller‐Ladner, U., Schäffler, A., & Karrasch, T. (2018) · Journal of Endocrinology · doi:10.1530/joe-18-0326 · Cited by 35
“Interestingly, type 2 diabetic patients treated with IL1-receptor antagonists display improved glycemic control and beta-cell function (Larsen et al. 2007).”
BackgroundFischer, B., Elias, D., Bretzel, R. G., & Linn, T. (2009) · Expert Opinion on Biological Therapy · doi:10.1517/14712590903555176 · Cited by 32
Sarrabay, G., Grandemange, S., & Touitou, I. (2015) · Expert Review of Clinical Immunology · doi:10.1586/1744666x.2015.1047765 · Cited by 32
Regulation of Metabolic Disease-Associated Inflammation by Nutrient Sensors
Yamashita, A. S., Belchior, T., Lira, F. S., BISHOP, N. C., Wessner, B., Neto, J. C. R., & Festuccia, W. T. (2018) · Mediators of Inflammation · doi:10.1155/2018/8261432 · Cited by 35
Ghanim, H., Dhindsa, S., Batra, M., Green, K., Abuaysheh, S., Kuhadiya, N. D., Makdissi, A., Chaudhuri, A., Sandhu, S., & Dandona, P. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgz288 · Cited by 32
Inhibition of IL-1beta improves Glycaemia in a Mouse Model for Gestational Diabetes
Schulze, F., Wehner, J., Kratschmar, D. V., Makshana, V., Meier, D. T., Häuselmann, S. P., Dalmas, É., Thienel, C., Dror, E., Wiedemann, S. J., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-59701-0 · Cited by 33
Self-citationInflammasome activation and metabolic disease progression
Li, H., Jin, C., Chen, Y., & Flavell, R. A. (2014) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2014.07.020 · Cited by 35
Non-Alcoholic Steatohepatitis: From Pathophysiology to Novel Therapies
Jahn, D., Rau, M., Wohlfahrt, J., Hermanns, H. M., & Geier, A. (2016) · Digestive Diseases · doi:10.1159/000444547 · Cited by 34
Younis, A., Eskenazi, D., Goldkorn, R., Leor, J., Naftali-Shani, N., Fisman, E. Z., Tenenbaum, A., Goldenberg, I., & Klempfner, R. (2017) · Cardiovascular Diabetology · doi:10.1186/s12933-017-0551-5 · Cited by 32
Clinical Immunologic Interventions for the Treatment of Type 1 Diabetes
Chatenoud, L., Warncke, K., & Ziegler, A. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a007716 · Cited by 33
The diverse roles of macrophages in metabolic inflammation and its resolution
Ray, A. G., Odum, O., Wiseman, D., & Weinstock, A. (2023) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2023.1147434 · Cited by 34
“Importantly, it was shown in a clinical trial that Anakinra, an IL-1 receptor antagonist, improves systemic inflammation and glycemia, with no effect on insulin sensitivity in type II diabetes patients (Larsen et al., 2007).”
BackgroundNeuro-endocrine-immune regulation of metabolic homeostasis
Xie, C., Lin, Y., Qi, C., Wang, W., Yuan, Y., Song, D., Wang, Z., Liu, H., Feng, X., & Gao, H. (2025) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2025.08.001 · Cited by 36
Vachliotis, I. D., & Pοlyzos, S. A. (2025) · Current Obesity Reports · doi:10.1007/s13679-025-00657-5 · Cited by 33
Gattu, A. K., Birkenfeld, A. L., Iwakiri, Y., Jay, S. M., Saltzman, W. M., Doll, J. A., Protiva, P., Samuel, V. T., Crawford, S. E., & Chung, C. (2014) · Endocrinology · doi:10.1210/en.2013-1785 · Cited by 33
Macrophage CGI-58 deficiency promotes IL-1β transcription by activating the SOCS3–FOXO1 pathway
Miao, H., Ou, J., Zhang, X., Chen, Y., Xue, B., Shi, H., Gan, L., Yu, L., & Liang, H. (2014) · Clinical Science · doi:10.1042/cs20140414 · Cited by 31
Tran, U. T., & Kitami, T. (2018) · Communications Biology · doi:10.1038/s42003-018-0244-y · Cited by 32
Pirklbauer, M., Bernd, M., Fuchs, L., Staudinger, P., Corazza, U., Leierer, J., Mayer, G. J., & Schramek, H. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21218189 · Cited by 34
“IL-1β antagonism reduces systemic inflammation in type II diabetic patients [35] and had beneficial effects on diabetes-related CKD in murine studies [36,37].”
BackgroundAnti-NLRP3 Inflammasome Natural Compounds: An Update
Liu, B., & Yu, J. (2021) · Biomedicines · doi:10.3390/biomedicines9020136 · Cited by 36
Activation and Regulation of NLRP3 by Sterile and Infectious Insults
Banerjee, S. K., Chatterjee, A., Gupta, S., & Nagar, A. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.896353 · Cited by 37
Pharmacological inhibitors of β-cell dysfunction and death as therapeutics for diabetes
Dalle, S., Abderrahmani, A., & Renard, É. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1076343 · Cited by 33
“Treatment with anakinra led to improved glycemia by increasing b-cell function (23).”
BackgroundInfluential
Metadata
- Authors
- Larsen, C. M., Faulenbach, M., Vaag, A., Vølund, A., Ehses, J. A., Seifert, B., Mandrup-Poulsen, T., & Donath, M. Y.
- Affiliations
- University Hospital Zurich (CH)
- Steno Diabetes Centers (DK)
- University of Zurich (CH)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2007-04-12
- Volume
- 356
- Issue
- 15
- Pages
- 1517-1526
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2024378513
- Cited by
- 1,798
- References
- 29
- Citations by year
- 2026: 41 · 2025: 47 · 2024: 61 · 2023: 75 · 2022: 89 · 2021: 97 · 2020: 84 · 2019: 83 · 2018: 87 · 2017: 77 · 2016: 111 · 2015: 113 · 2014: 135 · 2013: 141 · 2012: 132
- FWCI
- 93.91
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Zurich Open Repository and Archive (University of Zurich) (acceptedVersion, other-oa)
- Lund University Publications (Lund University) (submittedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (submittedVersion)
- Zurich Open Repository and Archive (University of Zurich) (submittedVersion, other-oa)
- Zurich Open Repository and Archive (University of Zurich)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
- Keywords
- anakinra, interleukin-1 receptor antagonist, type 2 diabetes, IL-1β, beta-cell function, insulin secretion, HbA1c, systemic inflammation, interleukin-6, C-reactive protein, C-peptide, hyperinsulinemic-euglycemic clamp, insulin resistance, adipokines
- MeSH terms
- Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha, Blood Glucose, C-Reactive Protein, Diabetes Mellitus, Type 2, Double-Blind Method, Female, Gene Expression Regulation, Glucose Tolerance Test, Heat-Shock Proteins, Glycated Hemoglobin, Humans, Insulin Resistance, Male, Middle Aged, Recombinant Proteins, RNA, Messenger, Transcription Factors, Interleukin-6, Body Mass Index, Receptors, Interleukin-1, Insulin-Secreting Cells, Glucose Transporter Type 4, Interleukin 1 Receptor Antagonist Protein
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.